SZLS — StageZero Life Sciences Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -388.51% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.19 | 0.14 | 4.15 | 5.07 | 3.8 | n/a | n/a | 55.93% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.
Directors
- James Howardtripp NEC
- Matthew Pietras CFO
- Heiner Dreismann LED (68)
- Richard Huston DRC
- Harry Glorikian IND (55)
- Garth Macrae IND (84)
- Rory Riggs IND (68)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2024
- Incorporated
- February 20th, 1997
- Public Since
- October 30th, 1998
- No. of Employees
- 40
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 123,553,050
- Address
- 30-70 East Beaver Creek Road, RICHMOND HILL, L4B 3B2
- Web
- https://www.stagezerolifesciences.com/
- Phone
- +1 9052092030
- Contact
- James Howard-Tripp
- Auditors
- SRCO Professional Corporation
Latest News for SZLS
Upcoming Events for SZLS
Q2 2024 StageZero Life Sciences Ltd Earnings Release
Q3 2024 StageZero Life Sciences Ltd Earnings Release
Similar to SZLS
Appili Therapeutics
Toronto Stock Exchange
Avicanna
Toronto Stock Exchange
Briacell Therapeutics
Toronto Stock Exchange
Cardiol Therapeutics
Toronto Stock Exchange
COSCIENS Biopharma
Toronto Stock Exchange
FAQ
As of Today at 23:26 UTC, shares in StageZero Life Sciences are trading at CA$0.04. This share price information is delayed by 15 minutes.
Shares in StageZero Life Sciences last closed at CA$0.04 and the price had moved by -55.56% over the past 365 days. In terms of relative price strength the StageZero Life Sciences share price has underperformed the Toronto Stock Exchange 300 Composite Index by -63.75% over the past year.
The overall consensus recommendation for StageZero Life Sciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreStageZero Life Sciences does not currently pay a dividend.
StageZero Life Sciences does not currently pay a dividend.
StageZero Life Sciences does not currently pay a dividend.
To buy shares in StageZero Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.04, shares in StageZero Life Sciences had a market capitalisation of .
Here are the trading details for StageZero Life Sciences:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: SZLS
Based on an overall assessment of its quality, value and momentum StageZero Life Sciences is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like StageZero Life Sciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -32.65%.
As of the last closing price of CA$0.04, shares in StageZero Life Sciences were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The StageZero Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
StageZero Life Sciences' management team is headed by:
- James Howardtripp - NEC
- Matthew Pietras - CFO
- Heiner Dreismann - LED
- Richard Huston - DRC
- Harry Glorikian - IND
- Garth Macrae - IND
- Rory Riggs - IND